Semaglutide biosimilar (Tonghua Dongbao Pharmaceutical)

N/A

Report date: 2025/01/26 17:04:50

Base Information

Drug NameSemaglutide biosimilar (Tonghua Dongbao Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A